Orthocell (ASX:OCC) reported a record quarterly revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, according to a Thursday Australian bourse filing.

The result represented the sixth consecutive quarter of record revenue, and it was primarily driven by increased market penetration in existing markets, particularly Australia and Singapore.

Growth in the sales of the firm's Remplir nerve repair product is expected to be further supplemented by market entry in Canada, the filing said. The expected adoption of Remplir by surgeons in the US represents a potential for an increase in revenue growth.